Author

D. T. Starczynowski

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:CITE-seq· 1 Organism:mouse· 1

Frequent Co-Authors

A. Pellagatti· 1 shared A. Shastri· 1 shared A. Verma· 1 shared A. Wickrema· 1 shared B. Agianian· 1 shared B. Will· 1 shared C. Ishikawa· 1 shared C. Walker· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Pellagatti

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJun 22, 2022

Chronic inflammation suppresses del(5q)-like MDS HSCs via p53

T. Muto, C. Walker, K. Choi…·D. T. Starczynowski

This study shows chronic inflammation impairs del(5q)-like MDS HSPCs by activating p53, leading to reduced quiescence and disease severity, which may drive p53 mutations in myeloid malignancies.

DOI 10.1101/2022.06.22.497183

mousehuman

𝕏 PostBluesky

Cancer BiologybioRxivMar 9, 2022

Activation of targetable inflammatory immune signaling is seen in Myelodysplastic Syndromes with SF3B1 mutations

G. Choudhary, A. Pellagatti, B. Agianian…·A. Verma

This study identifies a longer, oncogenic IRAK4 isoform caused by SF3B1 mutations in MDS/AML, which is targetable by IRAK4 inhibition.

DOI 10.7554/elife.78136

humanbulk RNA-seq

𝕏 PostBluesky